Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream genes. At the cellular level, p53 induces apoptosis, cell cycle arrest and senescence. A rare mutant form of p53 with the amino acid substitution R175P, found in human tumors, is completely defective in initiating apoptosis but still induces cell cycle arrest. To decipher the functional importance of these pathways in spontaneous tumorigenesis, we used homologous recombination to generate mice with mutant p53-R172P (the mouse equivalent of R175P in humans). Mice inheriting two copies of this mutation (Trp53(515C/515C)) escape the early onset of thymic lymphomas that characterize Trp53-null mice. At 7 months of age, 90% of Trp53-null mice had died, but 85% of Trp53(515C/515C) mice were alive and tumor-free, indicating that p53-dependent apoptosis was not required for suppression of early onset of spontaneous tumors. The lymphomas and sarcomas that eventually developed in Trp53(515C/515C) mice retained a diploid chromosome number, in sharp contrast to aneuploidy observed in tumors and cells from Trp53-null mice. The ability of mutant p53-R172P to induce a partial cell cycle arrest and retain chromosome stability are crucial for suppression of early onset tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cells harboring this mutation (p53P/P) are incapable of activating p53-dependent apoptosis59, but the p53-dependent cellular senescence pathway is intact as induction of telomere dysfunction through overexpression of TRF2-DN in these cells led to dramatic reduction of cellular proliferation and the appearance of senescent cells that stain positive for SA-β-Gal58.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [59]
Experimental — accuracy not yet measuredIn the citing paper
“Mice homozygous for the p.R172P mutation (equivalent to the human p.R175P alteration) exhibit defects in TP53‐dependent apoptosis but retain a partial cell cycle checkpoint function [44].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · cited 1×
“p53-R172P weakly induced Cdkn1a (encoding p21), a crucial target of p53 in cell cycle contro”
Backgroundp53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“gif" NDATA ITEM> ]> The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream gene”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Trp53 -null mice succumb to early tumorigenesis, predominantly thymic lymphoma”
Backgroundp53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864 · cited 1×
“To confirm this finding, we measured apoptosis in freshly isolated thymocytes after γ-radiatio”
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“gif" NDATA ITEM> ]> The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream gene”
BackgroundThymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · cited 1×
“Trp53 -null mice succumb to early tumorigenesis, predominantly thymic lymphoma”
BackgroundGenetic instability in colorectal cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386623a0 · Cited by 1,986 · cited 1×
“Genomic instability promotes tumorigenesis in multiple setting”
Cited by
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
“Despite being completely deficient in p53-driven apoptosis, these mice are still reasonably well protected from tumor development (Liu et al., 2004).”
BackgroundCell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
“This surprising result suggests that the growth arrest and chromosome stability functions of p53 provide tumour suppressor function even in the absence of its role in apoptosi”
BackgroundVousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
“1 ), including apoptosis, cell-cycle arrest, maintenance of genomic stability and senescenc”
BackgroundKastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Senescence in Health and Disease
He, S., & Sharpless, N. E. (2017) · Cell · doi:10.1016/j.cell.2017.05.015 · Cited by 1,766
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
“Recently, it was also shown that the interaction between mutant p53 and NF-Y is mediated by TopBP1 (Liu et al. 2011).”
BackgroundThe Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
“When the human-derived p53 mutations were introduced into the mouse germline, the p53-R172P (equivalent of human R175P) mutant mice were largely protected from spontaneous thymic lymphomas, suggesting that apoptosis was not needed for tumor suppression (Liu et al. 2004).”
BackgroundGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Self-citationThe signals and pathways activating cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.10.013 · Cited by 1,046
Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis
Grady, W. M., & Carethers, J. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.076 · Cited by 960
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
“Nevertheless, early-onset tumor formation is not observed in mice expressing an apoptosis-defective mutant (p53) that retains the cell-cycle arrest and cellular senescence functions of p53 (Liu et al., 2004; Cosme-Blanco et al., 2007;Van Nguyen et al., 2007).”
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
“mouse strains have been previously described (8, 12, 20, 22, 29, 41, 42).”
BackgroundMethodtp53 mutant zebrafish develop malignant peripheral nerve sheath tumors
Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D., Kutok, J. L., Fletcher, C. D. M., Morris, J. P., Liu, T. X., Schulte-Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 597
Tumor Suppressive Functions of p53
Zilfou, J. T., & Lowe, S. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001883 · Cited by 575
“One p53 mutant (containing the amino acid substitution R175P) is completely defective at inducing apoptosis, but can still induce cell-cycle arrest (Liu et al. 2004a).”
BackgroundMalkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 420
Telomere dysfunction and tumour suppression: the senescence connection
Deng, Y., Chan, S. S., & Chang, S. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2393 · Cited by 411
“Cells harbouring this mutation ( Trp53 P/P ) are incapable of activating p53-dependent apoptosi”
BackgroundSelf-citationThe role of mutant p53 in human cancer
Goh, A. M., Coffill, C. R., & Lane, D. P. (2011) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398
p53 and breast cancer, an update
Lacroix, M., Toillon, R.-A., & Leclercq, G. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380
“Phosphorylation of Ser215 by the mitotic kinase serine/threonine protein kinase 15 (STK15) (also known as Aurora A) abrogates p53 DNA binding and transactivation activity (Liu et al. 2004b).”
BackgroundHemann, M. T., & Lowe, S. W. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401962 · Cited by 370
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
“…can stimulate cell proliferation an order to accurately predict clinical response of TP53-mutated mice is similarly resistant (Lang et al., 2004; Liu et al., 2004). p53 also contributes to response after exposure to DNAdamaging drugs by inducing apoptosis in E1A/Ras-transformed mouse embryo…”
Self-citationp53 and Tumor Suppression: It Takes a Network
Boutelle, A. M., & Attardi, L. D. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.12.011 · Cited by 317
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells
Yang, Y., Ludwig, R. L., Jensen, J. P., Pierre, S. A., Medaglia, M. V., Davydov, I. V., Safiran, Y. J., Oberoi, P., Kenten, J. H., Phillips, A. C., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.029 · Cited by 322
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
“R172P in mice) is delayed compared with TP53− /− mice or mice expressing hotspot mutations.(72) In contrast to tumors expressing other p53 mutants, these tumors were mostly diploid, indicating that the growth arrest function of TP53 could be essential for maintaining genetic stability, but is not the primary tumor sup…”
BackgroundA spatially and temporally restricted mouse model of soft tissue sarcoma
Kirsch, D. G., Dinulescu, D. M., Miller, J. B., Grimm, J., Santiago, P. M., Young, N. P., Nielsen, G. P., Quade, B. J., Chaber, C. J., Schultz, C. P., et al. (2007) · Nature Medicine · doi:10.1038/nm1602 · Cited by 301
“Mice expressing the Trp53 R175P knock-in allele, which is defective in p53-mediated apoptosis while retaining checkpoint functions, however, still suppressed tumor development compared with a strain lacking p53 (ref”
BackgroundApoptosis and genomic instability
Zhivotovsky, B., & Kroemer, G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1443 · Cited by 299
“In accordance with this particular interpretation, a knock-in mutation of p53, which maintained the p53-mediated G1-phase arrest (through its capacity to induce p21) but abolished the pro-apoptotic function of p53, reduced the frequency of thymic lymphomas as well as the degree of aneuploidy found in such tumours, com…”
ResultValente, L. J., Gray, D. H. D., Michalak, E. M., Pinon-Hofbauer, J., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 291
“Additional roles for G1/S boundary cell-cycle arrest and cellular senescence have also been proposed (Liu et al., 2004; Riley et al., 2008; Vousden and Lane, 2007).”
BackgroundNoxa: at the tip of the balance between life and death
Ploner, C., Kofler, R., & Villunger, A. (2008) · Oncogene · doi:10.1038/onc.2009.46 · Cited by 283
“Interestingly, studies with knock-in mice that express an apoptosis-defective, but cell-cycle inhibitory competent mutant of p53 (R172P) indicate an equally prominent role for these two p53 functions in the suppression of thymic lymphoma development (Liu et al., 2004).”
Backgroundp53 mutation heterogeneity in cancer
Soussi, T., & Lozano, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.190 · Cited by 275
Self-citationThe Role of Aneuploidy in Cancer Evolution
Sansregret, L., & Swanton, C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028373 · Cited by 266
“…p53 mutant (R175P in human) defective for apoptotic induction but that retains cell-cycle arrest functions, showed delayed lymphomagenesis compared with TP532/2 mice and only gave rise to diploid tumors, an effect which was entirely dependent on p21 induction (Liu et al. 2004; Barboza et al. 2006).”
BackgroundCancer, Oxidative Stress, and Metastasis
Gill, J. G., Piskounova, E., & Morrison, S. J. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030791 · Cited by 266
“…increased DNA damage in the absence of p53 can be partially rescued by treatment with the antioxidant N- acetylcysteine (NAC), suggesting that the effects of p53 on redox homeostasis are a significant component of its functions that promote genomic stability (Liu et al. 2004; Sablina et al. 2005).”
BackgroundCellular senescence in vivo: a barrier to tumorigenesis
Prieur, A., & Peeper, D. S. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.007 · Cited by 260
Inherited TP53 Mutations and the Li–Fraumeni Syndrome
Guha, T., & Malkin, D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026187 · Cited by 253
“Most interestingly, Trp515C/515C mice were found to have a delayed tumor onset compared with homozygous mutant mice, suggesting delayed cell-cycle arrest to contribute to tumor suppression (Liu et al. 2004).”
p53 is a suppressor of inflammatory response in mice
Komarova, E. A., Krivokrysenko, V., Wang, K., Neznanov, N., Chernov, M. V., Komarov, P. G., Brennan, M., Golovkina, T. V., Rokhlin, O., Kuprash, D. V., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3213fje · Cited by 247
“p53-dependent apoptosis as a result of knockouts of p53-responsive apoptotic genes (Noxa, Puma) (1) or mice inheriting p53 mutant defective only in apoptotic function (p53-R172P) (2) showed no severe cancer predisposition, suggesting that additional mechanisms should exist through which p53 exerts its tumor suppressor…”
BackgroundSquatrito, M., Brennan, C. W., Helmy, K., Huse, J. T., Petrini, J. H., & Holland, E. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.034 · Cited by 238
“Relative to p53 / mice, in which both apoptosis and G1/S checkpoint control are abrogated, tumor latency in p53 mice is markedly increased (Liu et al., 2004).”
Backgroundp53 alterations in human cancer: more questions than answers
Soussi, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210280 · Cited by 232
“In a recent analysis of p53 alterations in a panel of 56 colorectal cancer cell lines, Liu et al. (2004) found that among the 22 cell lines that carried either missense or frameshift mutations, 12 expressed a truncated protein.”
Backgroundp53 Regulates Cell Cycle and MicroRNAs to Promote Differentiation of Human Embryonic Stem Cells
Jain, A. K., Allton, K., Iacovino, M., Mahen, E., Milczarek, R. J., Zwaka, T. P., Kyba, M., & Barton, M. C. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001268 · Cited by 227
“Interestingly, Dox induction of a mutated form of p53, p53R175P, known to induce cell cycle arrest but not apoptosis in mouse models [47,48] led to loss of OCT4 expression, although the decrease was smaller than the significant reduction induced by p53WT (Figure 5A and 5C).”
Deconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.171 · Cited by 227
“One such strain – the Trp53 strain (also known as Trp53) – harbors a human tumor-derived mutation at the orthologous murine residue.(42) p53 is defective in mounting an apoptotic response to DNA damage and oncogene activation, but retains partial activity in irradiation-induced cell cycle arrest.”
BackgroundActivating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination
Yan, C., Lu, D., Hai, T., & Boyd, D. D. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600712 · Cited by 214
“After 48 h, supernatants were harvested and used to infect MEFs in the presence of 4 mg/ml polybrene (Sigma) twice at 8 h intervals (Liu et al, 2004).”
Methodp53 modulates homologous recombination by transcriptional regulation of the RAD51 gene
Arias‐Lopez, C., Lazaro‐Trueba, I., Kerr, P., Lord, C. J., Dexter, T., Iravani, M., Ashworth, A., & Silva, A. (2006) · EMBO reports · doi:10.1038/sj.embor.7400587 · Cited by 206
“Both deficient and exacerbated HR activity determine genome instability (Tutt et al, 2001; Richardson et al, 2004), which is directly implicated in tumour progression (Liu et al, 2004).”
BackgroundCosme‐Blanco, W., Shen, M., Lazar, A. J. F., Pathak, S., Lozano, G., Multani, A. S., & Chang, S. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7400937 · Cited by 205
“…| 2007 scientificreportscientific report 497 To determine the relative contribution of apoptosis compared with cell-cycle arrest in p53-mediated tumour suppression by dysfunctional telomeres in vivo, we used a genetic approach on the basis of our previously reported p53R172P mice (Liu et al, 2004).”
BackgroundMethodResultInfluentialSelf-citationKim, J., Yu, L., Chen, W., Xu, Y., Wu, M., Todorova, D., Tang, Q., Feng, B., Jiang, L., He, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.012 · Cited by 202
Toledo, F., Krummel, K. A., Lee, C. J., Liu, C.-W., Rodewald, L.-W., Tang, M., & Wahl, G. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.014 · Cited by 199
“278 CANCER CELL APRIL 2006 p53R172P protein does not efficiently suppress tumor growth in clones where oncogenic events have occurred (Liu et al., 2004).”
BackgroundInfluentialDeconstructing p53 transcriptional networks in tumor suppression
Bieging, K. T., & Attardi, L. D. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.006 · Cited by 194
20 years studying p53 functions in genetically engineered mice
Donehower, L. A., & Lozano, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2731 · Cited by 168
“An R172P mutation produces a separation-of-function protein that retains the ability to arrest the cell cycle and partially activate p21 but is ineffective at inducing apoptosi”
BackgroundSelf-citationPathways connecting telomeres and p53 in senescence, apoptosis, and cancer
Artandi, S. E., & Attardi, L. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.211 · Cited by 191
Laud, P. R., Multani, A. S., Bailey, S. M., Wu, L., Ma, J., Kingsley, C., Lebel, M., Pathak, S., DePinho, R. A., & Chang, S. (2005) · Genes & Development · doi:10.1101/gad.1321305 · Cited by 190
“pBabe vector DNA or pBabe-H-Ras as described (Liu et al. 2004).”
BackgroundMethodSelf-citationOutcomes of p53 activation - spoilt for choice
Vousden, K. H. (2006) · Journal of Cell Science · doi:10.1242/jcs.03293 · Cited by 189
“Whereas activation of apoptosis in developing cancer cells would clearly be an efficient inhibitor of tumour development, mice engineered to express p53 that retains only the cell-cycle-arrest function are remarkably tumour resistant (Liu et al., 2004).”
BackgroundComplicating the complexity of p53
Yee, K. S., & Vousden, K. H. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi122 · Cited by 188
Schvartzman, J.-M., Duijf, P. H. G., Sotillo, R., Coker, C., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.017 · Cited by 181
“We used a previously developed p53 knockin model in which both p53 copies are replaced by alleles expressing the p53 mutant (p53) (Liu et al., 2004).”
InfluentialSuppression of tumorigenesis by the p53 target PUMA
Hemann, M. T., Zilfou, J. T., Zhao, Z., Burgess, D. J., Hannon, G. J., & Lowe, S. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403286101 · Cited by 179
The ATM signaling network in development and disease
Stracker, T. H., Roig, I., Knobel, P. A., & Marjanović, M. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00037 · Cited by 173
“…SMC1 (structural maintenance of chromosomes proteins), ATF2, the Mre11 complex and additional enzymes involved in the activation of the related ATR kinase and checkpoint kinase 1 (Chk1) through the generation of single-stranded DNA (ssDNA) tails (Shiotani and Zou, 2009; Stracker and Petrini, 2011).”
BackgroundBH3-only proteins in cell death initiation, malignant disease and anticancer therapy
Labi, V, Erlacher, M., Kiessling, S., & Villunger, A. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401940 · Cited by 167
“(R172P) indicate an equally prominent role for these two p53 functions in the suppression of thymic lymphoma development.(72) Cross-breeding experiments generating puma / / p21 / or noxa / /p21 / double-mutant mice may reveal”
BackgroundCurrent understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163
The role of DNA damage responses in p53 biology
Speidel, D. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1459-z · Cited by 160
“Similar to the mutp53 R172P model, cells from these mice could induce p53-mediated cell cycle arrest but not apoptosis in response to DNA damage (Liu et al. 2004; Slatter et al. 2010).”
BackgroundResultCancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism
Gorbunova, V., Hine, C., Tian, X., Ablaeva, J., Gudkov, A. V., Nevo, E., & Seluanov, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217211109 · Cited by 163
“These mice show longer tumor latency than p53 mice, but are more tumor-prone than the wild-type mice (13).”
BackgroundEischen, C. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026096 · Cited by 161
Ser18 and 23 phosphorylation is required for p53‐dependent apoptosis and tumor suppression
Chao, C., Herr, D., Chun, J., & Xu, Y. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601167 · Cited by 158
“Since p53-dependent apoptosis upon damage is greatly reduced in p53S18/23A mice, these findings support the recent conclusion that p53-dependent apoptosis is not essential for p53-depen- dent tumor suppression (Liu et al, 2004).”
BackgroundWild-Type p53: Tumors Can't Stand It
Kastan, M. B. (2007) · Cell · doi:10.1016/j.cell.2007.02.022 · Cited by 158
Telomerase, senescence and ageing
Shawi, M., & Autexier, C. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.11.007 · Cited by 172
“Mice with two copies of the p53 R172P allele cannot initiate a p53-dependent apoptosis response but retain an intact cell-cycle arrest pathway (Liu et al., 2004).”
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508500103 · Cited by 155
Self-citationMin, J.-N., Huang, L., Zimonjic, D. B., Moskophidis, D., & Mivechi, N. F. (2007) · Oncogene · doi:10.1038/sj.onc.1210317 · Cited by 170
“The results support the concept that Hsf1 acts as capacitor for tumor evolution in that its functional inactivation suppresses lymphoma development, a prominent tumor type frequently arising spontaneously in the p53 / mouse model (Harvey et al., 1993; Liu et al., 2004).”
BackgroundRogers, Z. N., McFarland, C. D., Winters, I. P., Naranjo, S., Chuang, C.-H., Petrov, D., & Winslow, M. M. (2017) · Nature Methods · doi:10.1038/nmeth.4297 · Cited by 147
“A Power-law distribution is consistent with p53-deficiency allowing tumors to acquire additional rare, yet profoundly tumorigenic events that drive subsequent rapid growth 28–30 .”
Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis
Garrison, S. P., Jeffers, J. R., Yang, C., Nilsson, J. A., Hall, M. A., Rehg, J. E., Yue, W., Yu, J., Zhang, L., Onciu, M., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00907-07 · Cited by 146
“Previous studies implicated the apoptotic arm of the p53 signaling pathway as its primary tumor suppressor function ( 30 , 40, 43, 45).”
BackgroundAbbas, H. A., Maccio, D. R., Coskun, S., Jackson, J. G., Hazen, A. L., Sills, T. M., You, M. J., Hirschi, K. K., & Lozano, G. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.09.013 · Cited by 142
“Mice We used previously describedMdm2+/ (Montes de Oca Luna et al., 1995) and p53515C/515C (Liu et al., 2004) mice.”
BackgroundMethodInfluentialSelf-citationThe UMD TP53 database and website: update and revisions
Hamroun, D., Kato, S., Ishioka, C., Claustres, M., Béroud, C., & Soussi, T. (2006) · Human Mutation · doi:10.1002/humu.20269 · Cited by 140
“These data are also emphasized by the observation that the distribution of tumors in Trp53 (Trp53 is the mouse gene encoding TP53) mice differs from that of mice harboring point mutations [Liu et al., 2004; Olive et al., 2004].”
BackgroundHow mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 148
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 144
“develop and succumb to different tumor types, predominantly lymphomas (Harvey et al., 1993; Jacks et al., 1994; Liu et al., 2004).”
BackgroundThe p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
Pant, V., Quintás-Cardama, A., & Lozano, G. (2012) · Blood · doi:10.1182/blood-2012-05-356014 · Cited by 129
Self-citationTumor suppressor p53 and its gain-of-function mutants in cancer
Liu, J., Zhang, C., & Feng, Z. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt144 · Cited by 157
Nitric Oxide, a Mediator of Inflammation, Suppresses Tumorigenesis
Hussain, S. P., Trivers, G. E., Hofseth, L. J., He, P., Shaikh, I., Mechanic, L. E., Doja, S., Jiang, W., Subleski, J., Shorts, L., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2201 · Cited by 128
“In addition, chromosomal stability was found to be important in the suppression of spontaneous tumorigenesis when p53-mediated apoptosis is compromised (31).”
BackgroundRath, N., Morton, J. P., Julian, L., Helbig, L., Kadir, S., McGhee, E. J., Anderson, K. I., Kalna, G., Mullin, M., Pinho, A. V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606743 · Cited by 127
A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development
Post, S. M., Quintás-Cardama, A., Pant, V., Iwakuma, T., Hamir, A., Jackson, J. G., Maccio, D. R., Bond, G. L., Johnson, D. G., Levine, A. J., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.010 · Cited by 127
“Tails from mice were genotyped for Mdm2 using forward primers 50-GCATTA GAGAGTGGTCACTGCGAC-30 and reverse primers 50-GAACAGTGATAGAA CATCATGTCAC-30 for the Mdm2 alleles and previously described primers for the p53 alleles (Jacks et al., 1994; Liu et al., 2004).”
Self-citationNew insights into p53 activation
Brooks, C. L., & Gu, W. (2010) · Cell Research · doi:10.1038/cr.2010.53 · Cited by 102
“[53] showed that mice harboring this mutation failed to develop the early-onset thymic lymphomas that p53-null mice did.”
BackgroundThe cancer biology of whole-chromosome instability
Duijf, P. H. G., & Benezra, R. (2013) · Oncogene · doi:10.1038/onc.2012.616 · Cited by 140
Deng, L., Yao, P., Li, L., Ji, F., Zhao, S., Xu, C., Lan, X., & Jiang, P. (2020) · Nature Communications · doi:10.1038/s41467-020-15573-6 · Cited by 121
Nacerddine, K., Beaudry, J.-B., Ginjala, V., Westerman, B., Mattiroli, F., Song, J.-Y., van der Poel, H., Ponz, O. B., Pritchard, C., Cornelissen-Steijger, P., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57477 · Cited by 113
“determine genome instability (56, 57), which is directly implicated in tumor progression (58).”
Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation
Ashur-Fabian, O., Avivi, A., Trakhtenbrot, L., Adamsky, K., Cohen, M., Kajakaro, G., Joel, A., Amariglio, N., Nevo, E., & Rechavi, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404998101 · Cited by 112
p21 delays tumor onset by preservation of chromosomal stability
Barboza, J. A., Liu, G., Ju, Z., El-Naggar, A. K., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606343104 · Cited by 110
Self-citationApoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation
Labi, V., Erlacher, M., Krumschnabel, G., Manzl, C., Tzankov, A., Pinon, J., Egle, A., & Villunger, A. (2010) · Genes & Development · doi:10.1101/gad.1940210 · Cited by 109
“Consistently, thymic lymphomas from p53 / and p53 mutant knock-in mice show frequent aneuploidy (Liu et al. 2004; Morales et al. 2006).”
BackgroundMutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
Kim, M. P., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 108
“For example, the p53R172P mutation, albeit rare, is able to activate the cell cycle arrest but not apoptotic programs of p53 (48).”
BackgroundSelf-citationKrüppel-like factor 4 exhibits antiapoptotic activity following γ-radiation-induced DNA damage
Ghaleb, A. M., Katz, J. P., Kaestner, K. H., Du, J. X., & Yang, V. W. (2006) · Oncogene · doi:10.1038/sj.onc.1210022 · Cited by 125
Beyond the Oncogene Paradigm: Understanding Complexity in Cancerogenesis
Bizzarri, M., Cucina, A., Conti, F., & D’Anselmi, F. (2008) · Acta Biotheoretica · doi:10.1007/s10441-008-9047-8 · Cited by 115
Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?
Thomas, A., Kelly, G. L., & Strasser, A. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00996-z · Cited by 110
“The retention of chromosomal stability was therefore suggested to be crucial for the suppression of early onset tumorigenesis by allowing cells to undergo cell cycle arrest [75].”
Backgroundp53-Mediated Tumor Suppression: DNA-Damage Response and Alternative Mechanisms
Pitolli, C., Wang, Y., Candi, E., Shi, Y., Melino, G., & Amelio, I. (2019) · Cancers · doi:10.3390/cancers11121983 · Cited by 97
“Moreover, mouse embryonic fibroblasts (MEFs) obtained from p53R172P/R172P mice also retain a diploid genome, unlike MEFs derived from p53− mice that become tetraploid after a few passages in culture [85].”
BackgroundDisruption of Trp53 in Livers of Mice Induces Formation of Carcinomas With Bilineal Differentiation
Katz, S., Lechel, A., Obenauf, A. C., Begus‐Nahrmann, Y., Kraus, J. M., Hoffmann, E. M., Duda, J., Eshraghi, P., Hartmann, D., Liss, B., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.009 · Cited by 111
Lozano, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001115 · Cited by 94
“p53 mutant knockin mice with the equivalent mutation at amino acid 172 clearly show an important role of p53 cell-cycle arrest function in tumor suppression (Liu et al. 2004).”
BackgroundSelf-citationHow the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor
Ho, T., Tan, B. X., & Lane, D. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010013 · Cited by 100
“R172P mutant mice also retain partial tumor suppressive capabilities [13].”
BackgroundHeterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
Monti, P., Menichini, P., Speciale, A., Cutrona, G., Fais, F., Taìana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593383 · Cited by 107
“In contrast, the R172P mutation in mice (corresponding to the human R175P, PF mutation) caused a delayed tumorigenesis rate with absence of chromosomal instability (38).”
BackgroundThe p53 tumor suppressor protein regulates hematopoietic stem cell fate
Asai, T., Liu, Y., Bae, N., & Nimer, S. D. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22561 · Cited by 111
“…p53 on HSC quiescence, understanding how p53 promotes quiescence may lead to therapeutic strategies that could eliminate the largely quiescent LSCs (Liu et al., 2009). p53 mutations are found in a minority of human leukemias, and if p53 signaling is intact, then disrupting the p53-MDM2 interact…”
BackgroundMethodInfluentialIn vivo analysis of p53 tumor suppressor function using genetically engineered mouse models
Broz, D. K., & Attardi, L. D. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp331 · Cited by 67
p53, a translational regulator: contribution to its tumour-suppressor activity
Marcel, V., Catez, F., & Diaz, J. (2015) · Oncogene · doi:10.1038/onc.2015.25 · Cited by 96
NAD+ Modulates p53 DNA Binding Specificity and Function
McLure, K. G., Takagi, M., & Kastan, M. B. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9958-9967.2004 · Cited by 88
“This suggests that functions other than apoptosis must be able to contribute to p53 tumor suppressor activity (30).”
BackgroundKakudo, Y., Shibata, H., Otsuka, K., Kato, S., & Ishioka, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2935 · Cited by 88
E2F3 Is a Mediator of DNA Damage-Induced Apoptosis
Martinez, L. A., Goluszko, E., Chen, H., Leone, G. W., Post, S. M., Lozano, G., Chen, Z., & Chauchereau, A. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00938-09 · Cited by 99
“Therefore, we used a well-established in vivo model in which pregnant female mice are irradiated and then the embryos are harvested to determine the apoptotic response in the developing central nervous system (CNS) (19).”
MethodInfluentialSelf-citationPathophysiological Functions of the lncRNA TUG1
Guo, C., Qi, Y., Qu, J., Gai, L., Shi, Y., & Yuan, C. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612826666191227154009 · Cited by 91
The mitotic checkpoint in cancer and aging: what have mice taught us?
Baker, D. J., Chen, J., & van Deursen, J. M. A. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.011 · Cited by 87
Metadata
- Authors
- Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Lozano, Guillermina
- Venue
- Nature Genetics
- Published
- 2003-12-21
- Volume
- 36
- Issue
- 1
- Pages
- 63-68
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1970378023
- Cited by
- 325
- References
- 30
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 12 · 2019: 15 · 2018: 9 · 2017: 11 · 2016: 16 · 2015: 5 · 2014: 15 · 2013: 18 · 2012: 19
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kadoorie Charitable Foundation
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- p53, chromosome stability, apoptosis, tumor suppression, spontaneous tumor development, thymic lymphoma, sarcoma, aneuploidy, cell cycle arrest, senescence, diploidy
- MeSH terms
- Animals, Cell Cycle, Lymphoma, Mice, Mutant Strains, Ploidies, Genes, p53, Apoptosis, Chromosomal Instability, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.